The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Saved in:

Bibliographic Details
Title:	The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Authors:	Gerstein HC (AUTHOR), Swedberg K (AUTHOR), Carlsson J (AUTHOR), McMurray JJV (AUTHOR), Michelson EL (AUTHOR), Olofsson B (AUTHOR), Pfeffer MA (AUTHOR), Yusuf S (AUTHOR), CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program Investigators (CORPORATE AUTHOR)
Source:	Archives of Internal Medicine. 8/11/2008, Vol. 168 Issue 15, p1699-1704. 6p.
Database:	Academic Search Ultimate

Description
ISSN:	00039926
DOI:	10.1001/archinte.168.15.1699